An anti-perfringolysin O monoclonal antibody cross-reactive with streptolysin O protects against streptococcal toxic shock syndrome

• Published in: BMC research notes Vol. 13; no. 1; pp. 419 - 6
• Main Authors: Matsumura, Takayuki, Nishiyama, Ayae, Aiko, Michio, Ainai, Akira, Ikebe, Tadayoshi, Chiba, Joe, Ato, Manabu, Takahashi, Yoshimasa
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 05.09.2020; BioMed Central; BMC
• Subjects: Animals; Antibiotics; Antibodies, Monoclonal; Bacteria; Bacterial Proteins; Bacterial Toxins; Care and treatment; Cholesterol; Cholesterol-dependent cytolysins; Clinical isolates; Cross-reactivity; Cytolysins; Experiments; Hemolysin Proteins; Infections; Infectious diseases; Leukocytes (neutrophilic); Medical prognosis; Mice; Mice, Inbred C57BL; Monoclonal antibodies; Neutralizing monoclonal antibody; Neutrophils; Perfringolysin O; Prevention; Research Note; Septic shock; Shock, Septic - drug therapy; Shock, Septic - prevention & control; Statistical analysis; Streptococcal Infections - drug therapy; Streptococcal Infections - prevention & control; Streptococcal toxic shock syndrome; Streptococcus; Streptococcus pyogenes; Streptolysin O; Streptolysins; Testing; Toxic shock syndrome; Virulence; Working groups; Japan; United Kingdom > UK; Cholesterol-dependent cytolysins; Perfringolysin O; Streptolysin O; Neutralizing monoclonal antibody; Streptococcal toxic shock syndrome

Streptococcus pyogenes (Group A Streptococcus; GAS) causes a variety of infections that include life-threatening, severe invasive GAS infections, such as streptococcal toxic shock syndrome (STSS), with > 30% mortality rate, despite effective antibiotics and treatment options. STSS clinical isolat...